ALKS:NGS-Alkermes plc (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | Nasdaq Global Select

Last Closing

USD 35.9

Change

+0.01 (+0.03)%

Market Cap

USD 8.87B

Volume

2.20M

Analyst Target

USD 19.73
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-18 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

+0.29 (+0.25%)

USD 15.37B
ITCI Intracellular Th

+0.64 (+0.50%)

USD 13.50B
VTRS Viatris Inc

+0.07 (+0.64%)

USD 13.01B
LNTH Lantheus Holdings Inc

-2.02 (-2.42%)

USD 6.78B
ALVO Alvotech

-0.86 (-6.84%)

USD 3.84B
HCM HUTCHMED DRC

+1.11 (+8.09%)

USD 2.39B
SUPN Supernus Pharmaceuticals Inc

-6.23 (-15.67%)

USD 2.13B
AMPH Amphastar P

+0.46 (+1.50%)

USD 1.75B
DVAX Dynavax Technologies Corporati..

+0.16 (+1.24%)

USD 1.69B
EVO Evotec SE ADR

-0.21 (-4.54%)

USD 1.65B

ETFs Containing ALKS

PSIL AdvisorShares Psychedelic.. 5.60 % 0.00 %

-0.20 (-0.15%)

USD 0.01B
FBT:LSE First Trust Global Funds .. 4.16 % 0.00 %

+14.90 (+-0.15%)

USD 8.65M
FBTU:LSE First Trust Global Funds .. 4.16 % 0.00 %

+0.07 (+-0.15%)

USD 8.62M
IBRN iShares Trust - iShares N.. 4.00 % 0.00 %

-0.23 (-0.15%)

USD 3.90M
PSCH Invesco S&P SmallCap Heal.. 3.40 % 0.29 %

+1.03 (+-0.15%)

USD 0.19B
TYNE 3.26 % 0.00 %

N/A

N/A
ETLZ:XETRA 0.65 % 0.00 %

N/A

N/A
VIDI Vident International Equi.. 0.55 % 0.63 %

-0.20 (-0.15%)

USD 0.34B
GVLU Tidal ETF Trust 0.50 % 0.00 %

-0.04 (-0.15%)

USD 0.18B
LABS 0.00 % 0.45 %

N/A

N/A
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

+0.14 (+-0.15%)

USD 0.09B
RTWO:LSE L&G Russell 2000 US Small.. 0.00 % 0.00 %

+0.08 (+-0.15%)

USD 0.24B
RTWP:LSE Legal & General UCITS ETF.. 0.00 % 0.00 %

+36.50 (+-0.15%)

USD 0.24B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.83% 85% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.83% 85% B 89% A-
Trailing 12 Months  
Capital Gain 18.13% 75% C 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.13% 75% C 68% D+
Trailing 5 Years  
Capital Gain 75.72% 87% B+ 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 75.72% 87% B+ 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 11.91% 53% F 64% D
Dividend Return 11.91% 53% F 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.19% 85% B 67% D+
Risk Adjusted Return 43.79% 87% B+ 73% C
Market Capitalization 8.87B 94% A 88% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.77 60% 61%
Price/Book Ratio 4.00 36% 31%
Price / Cash Flow Ratio 12.71 23% 24%
Price/Free Cash Flow Ratio 11.66 27% 32%
Management Effectiveness  
Return on Equity 29.23% 94% 94%
Return on Invested Capital 36.16% 97% 93%
Return on Assets 8.98% 91% 94%
Debt to Equity Ratio 23.92% 45% 57%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.